Sector: Life Sciences

Latest content

Top university IP head voices concerns about new UK foreign investment law

Imperial College tech transfer chief Vjera Magdalenic-Moussavi says the recent legislation puts dealmaking in danger

23 August 2022

From academy to industry: China’s new trend and policies on academic technology transfer

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

Most universities and research institutes in China are government-funded, and university­-generated intellectual property is considered state-owned property, making concern over the improper disposal, or even loss of, state-owned property the most prominent issue of academic technology transfers.

18 August 2022

Legal and strategic questions surrounding biologic and biosimilar litigation

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

While biologics have been officially recognised in Mexican law since 2009, innovators need to be aware of the regulatory regime governing these biotech products.

18 August 2022

Unified Patent Court: an introduction for life sciences companies

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

The UPC is expected to become operational in early 2023. The new court will provide a one-stop shop for patent litigation throughout a large part of Europe, with decisions being made by one centralised court.

18 August 2022

How to successfully protect antibodies at the EPO

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

Antibody therapies are booming, with a majority of the top 10 blockbuster drugs now antibodies. The introduction of a section dedicated to antibody drafting in the Guidelines for Examination at the European Patent Office in March 2021 is an illustration of the importance of antibody patenting.

18 August 2022

Protecting second medical use inventions in Europe

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

Given the immense costs that are associated with developing new chemical entities for therapy, the repurposing of already available drugs is an attractive approach for the pharmaceutical industry. The fact that most patent systems provide protection for second medical use inventions encourages and fosters innovation in this area.

18 August 2022

Written description: a death knell to genus claims in biotechnology

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

Recently, US courts have restricted the protections afforded to biotechnology by expanding the written description requirements. Regardless of whether this is intended to curb the perceived effect of patents on healthcare costs or to harmonise US patent law across technologies, the effect may be decreased investment in US biotechnology.

18 August 2022

Winning IP strategies for small and medium-sized biotechs

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

With the advancement in technologies related to various life sciences fields, the world has seen a significant increase in the number of SMEs in different fields in the life sciences sector, such as pharmaceuticals and biotechnology. SMEs related to biotechnology have contributed to the global market by developing breakthrough products such as therapeutic bio drugs (peptides, antibodies, etc), biomedical devices (biofilms, etc) and diagnostic tools.

18 August 2022

Why brand-name pharmaceuticals should look to China’s patent linkage system

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

China has recently introduced a unique patent linkage system, which has opened up fresh opportunities for those brand-name pharmaceutical companies that adapt their IP strategies to it.

18 August 2022

Tips and tricks on how to obtain patent protection for polymorphs

Featured in IAM Life Sciences: Key issues for senior life sciences executives 2022

Obtaining patent protection for a polymorph in addition to a primary compound patent may be particularly advantageous, especially if filed successively, as the polymorph patent may add extra time to the patent protection for the modification of an approved drug or a clinical candidate.

18 August 2022

Unlock unlimited access to all IAM content